Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping
11.8.2026 07:00:00 CEST | Business Wire | Press release
Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1 Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3 It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4
Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810880899/en/
The lower face plays a pivotal role in overall facial balance, influencing proportions and profile.2 This region is an increasing area of concern for patients, with around one in four people expressing concerns related to lower face sagging and chin shape.5 When asked about their facial priorities, a third of people pointed out issues with their chin shape – a key contributor to facial definition and structural harmony.5 Genetic factors and age-related changes can lead to reduced chin definition and poor projection.2,6 Until now, achieving structure in this area has largely relied on surgical implants, with no minimally invasive injectable aesthetic alternatives available for patients.2
Powered by Galderma’s new NASHA HD™ technology, Restylane Shaype is the firmest HA injectable gel available among market leaders in the facial filler market, with the highest G’ (measure of firmness) of the Restylane range.2,3 As the first-and-only HA dermal filler specifically designed to allow aesthetic injectors to build and shape on the lower angles of the face, it provides greater projection with lower injection volumes.2,7,8 Underpinning the Restylane range is a minimally modified HA gel that closely resembles naturally occurring HA, requires less product than other HA gels, and can be readily reversed, offering both performance and reassurance.2,9-13
“Hyaluronic acid fillers remain the irreplaceable hero at the center of modern aesthetic care, yet the ability to achieve structural support in the face without surgery has long been limited. In my clinical practice, I have seen how Restylane Shaype can address this gap, supported by pivotal data demonstrating durable improvements in lower face structure and definition through 12 months, high patient satisfaction and strong willingness to repeat treatment. These findings mirror what I have been seeing in practice and highlight the value of a bone-mimicking HA injectable that enables predictable, natural-looking results aligned with individual patient anatomy and treatment goals.”
DR. ANDREI METELITSA, MD, FRCPC, DABD, COSMETIC DERMATOLOGIST RESTYLANE SHAYPE PIVOTAL STUDY INVESTIGATOR CANADA |
|
In a pivotal 12-month study, 83% of people treated with Restylane Shaype showed improved structure and definition at three months (66% at 12 months), and 84% of patients would agree to be treated with Restylane Shaype again.2 Furthermore, up to 97% of patients would recommend treatment with Restylane Shaype to a friend.2 Restylane Shaype injections are administered with a new, next-generation syringe to enhance precision and control through its ergonomic design and optimized syringe-needle connection.1,14
To support consistent, individualized use of Restylane Shaype in clinical practice, Galderma has developed the Shayping Technique™.15 The technique combines Galderma’s Assessment, Anatomy, Range, and Treatment (AART™) methodology and the Facial Assessment Scale (FAS), enabling healthcare professionals to systematically evaluate lower face anatomy and facial balance, helping to identify individual patient priorities and treatment goals.15,16 This assessment-led approach supports a broader understanding of lower face structure and is aligned with ongoing investigations of Restylane Shaype in areas such as the jawline.15,16
“The EU approval of Restylane Shaype represents an important regulatory milestone for Galderma and for injectable aesthetics more broadly. With approvals now spanning Europe, Canada, and Brazil, this first-and-only HA shaper is a valuable new addition to the overall aesthetic landscape, and to the Restylane portfolio, expanding clinicians’ ability to address structural concerns in ways that traditional HA fillers are not designed to. It reflects the strength of our clinical development capabilities and our commitment to delivering innovative, science-based solutions that respond to the increasing global demand for facial balancing.”
BALDO SCASSELLATI SFORZOLINI, M.D., Ph.D. GLOBAL HEAD OF R&D GALDERMA |
|
The distinctive bone-mimicking effect of Restylane Shaype reinforces how the Restylane HA treatment range is well-placed to address evolving aesthetic needs across all life stages, including aesthetic changes associated with medication-driven weight loss and menopause, which can affect bone density, structural support, and skin health. 2,8,17-19
With over 30 years of innovation and more than 77 million treatments administered worldwide, the Restylane portfolio offers a versatile range of HA gels that remain highly relevant in responding to today’s most significant aesthetic trends and needs.4,20,21 As patient expectations shift toward more effortless, always-on rejuvenation, Galderma’s ‘Wake Up To Restylane’ campaign positions Restylane as an everyday natural beauty ally for the face and other areas of the body, highlighting Galderma’s commitment to meeting emerging needs. Focused on the growing desire for natural, authentic results, the campaign underscores Restylane’s ability to deliver personalized outcomes that go beyond volumizing, helping people feel confident in their skin. 2,22,23
About the Restylane portfolio
Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results.1,4,23 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.24-26 Powered by NASHA®, NASHA HD™, OBT™ and SB-NASHA™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.2,3,27,28 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results.4,29,30 Approved indications vary by market.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References
- Restylane® EU Instructions for Use. July 2026.
- Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255–261. doi: 10.36849/JDD.8145.
- Galderma. Data on file. MA-56724. 2023. Global rheology data (xStrain and G´ including Restylane SHAYPE).
- Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.
- Galderma. Data on file. 2023. Restylane Shaype Consumer Study; Canada.
- Cole JB, et al. Human facial shape and size heritability and genetic correlations. Genetics. 2017; 205(2): 967-978. doi: 10.1534/genetics.116.193185.
- Nikolis A et al. Poster presentation: Effectiveness and Safety of a New NASHA-HD Hyaluronic Acid Injectable, HASHA, for Augmentation and Correction of Chin Retrusion. Presented at: IMCAS, 2024,Paris, France.
- Galderma. Data on file. MA-56848. 2023. Technical data for Restylane SHAYPE.
- Hilton S, et al. Randomized, evaluator-blinded study comparing safety and effect of two hyaluronic acid gels for lips enhancement. Dermatol Surg. 2018;44(2):261–269. doi: 10.1097/DSS.0000000000001282
- Nikolis A, et al. The CHEEKY study: effectiveness of cheek treatment with hyaluronic acid fillers HAVOL and HALYF. Poster presented at: AMWC, Monaco. 2022
- Andriopoulos B, et al. Facial augmentation with hyaluronic acid fillers in an Asian population. Poster presented at AMWC, Monaco. 2019.
- Jones D, et al. A randomized, comparator-controlled study of HARC for cheek augmentation and correction of midface contour deficiencies J Drugs Dermatol. 2021;20;949–956. doi:10 .36849 /JDD .6191
- Weiss R, et al. a randomized, controlled, evaluator-blinded, multi-center study of hyaluronic acid filler effectiveness and safety in lip fullness augmentation. Dermatol Surg. 2021;47(4):527–532. doi: 10.1097/DSS.0000000000002856
- Galderma. Data on file. Dekra Restylane next generation syringe report.
- Nikolis A, et al. The ARTIST post-marketing study: Evaluating a high G’ hyaluronic acid injectable for chin treatment in combination with other hyaluronic acid fillers for lower face and midface treatment. E-poster presented at AMWC; October 21-23, 2025; Dubai.
- Galderma. Data on file. AART Methodology Comprehensive Training Deck 2022.
- Kapoor KM, et al. Treating aging changes of facial anatomical layers with hyaluronic acid fillers. Clin Cosmet Investig Dermatol. 2021;14:1105-1118. doi: 10.2147/CCID.S294812.
- Fabi S, et al. The potential role of biostimulators/dermal fillers to address menopause related skin conditions. E-poster presented at IMCAS; October 21-23,2025; Dubai.
- Nikolis A, et al. Consensus Statements on Managing Aesthetic Needs in Prescription Medication-Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study. JCD. 2025;24: e70094. doi: 10.1111/jocd.70094.
- Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.
- Galderma. Data on file. MA-55607. Restylane® 27 years data publications analysis
- Galderma. Data on file. Global report: Aesthetics treatments and hyaluronic acid injectables. Consumers & HCPs. 2025.
- Galderma. Data on file. MA-48544 Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021.
- Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.
- Galderma. Data on file. MA-58650. Degree of modification of HA fillers.
- Kablik J, et al. Comparative physical properties of HA dermal fillers. Dermatol Surg. 2009; 35, 302–312. doi: 10.1111/j.1524-4725.2008.01046.x.
- Öhrlund Å et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance J Drugs Dermatol. 2024;23(1):1332–1336. doi: 10.36849/JDD.7648.
- Belmontesi M et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a Skin Quality Booster: An Expert Panel Consensus. J Drugs Dermatol. 2018;17(1):83–88.
- Solish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.
- Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.1320
View source version on businesswire.com: https://www.businesswire.com/news/home/20260810880899/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Secures Payment Institution Licence from the Central Bank of Brazil4.9.2026 16:41:00 CEST | Press release
Expanding the company’s capability to support local partners with FinAI solutions Ant International, the leading global digital payment, digitisation, and FinAI solutions provider, today announced that it has received a Payment Institution (PI) licence from the Central Bank of Brazil. “With the Central Bank's invaluable support, we are ready to step up more reliable and comprehensive global payment and account services to enterprises, platforms and SMEs in the country's dynamic digital economy, in ever deeper collaboration with its highly developed payments ecosystem and financial services industry,” said Rodrigo Reif, General Manager, Ant International Brazil. Ant International provides cross-border payments and account services, embedded credit and treasury services, and other finAI and blockchain solutions to clients across Asia, Europe and the Americas. The company processes over 20 million transactions daily, connecting 2 billion consumer accounts to 150 million global merchants v
Bending Spoons completes the acquisition of Airtable4.9.2026 14:30:00 CEST | Press release
Bending Spoons S.p.A. (NASDAQ: BSP) has completed the previously announced acquisition of Airtable, the platform used by more than 500,000 organizations to reshape how teams organize data and manage critical workflows. “Airtable continues to grow because customers value its best-in-class flexibility,” said Luca Ferrari, Bending Spoons CEO and co-founder. “Teams can bring all their data, context, and AI agents together in one place, shape their workflows around their specific needs, and progressively expand their use of the platform over time. As we take the reins, our focus will be on sustaining that growth by investing heavily in Airtable’s product, customer support, and go-to-market capabilities.” “I’m proud of what the Airtable team has built and excited to see the business enter this next chapter,” said Howie Liu, co-founder of Airtable. “I’m confident Bending Spoons has the resources and long-term perspective to help Airtable continue delivering exceptional value to its customers
EQT to acquire McGill and Partners, a leading specialty (re)insurance broker for USD 2.0 billion, from Warburg Pincus4.9.2026 13:48:00 CEST | Press release
Warburg Pincus and McGill and Partners have reached an agreement with EQT that will see Warburg Pincus sell its majority stake to EQT McGill and Partners founders, management team and colleagues will re-invest alongside EQT, retaining a meaningful ownership stake in the firm going forward as they continue to serve clients globally Maintains commitment to firm’s independent model and culture of ownership, developed organically since its founding in 2019 EQT will partner with Steve McGill and the management team to accelerate organic growth, including via talent recruitment, further development of technology and data capabilities, and expansion of innovative digital solutions EQT and McGill and Partners are pleased to announce that EQT X ("EQT") has entered into a definitive agreement to acquire a majority stake in McGill and Partners from Warburg Pincus for USD 2.0bn. Founder and Chief Executive Officer Steve McGill will continue to lead the firm, while Chairman John Lloyd will remain a
A Race Is Never Won Alone: With La Tavolata, Barilla Brings the Paddock Family Together on the Monza Grid4.9.2026 12:18:00 CEST | Press release
A nearly 100-meter-long dinner table hosted more than 200 guests for an evening celebrating collaboration, trust and the bonds built beyond competition. On Thursday evening ahead of the Formula 1® Italian Grand Prix, Barilla transformed one of the sport’s fastest and most competitive environments into a place where the Paddock Family took center stage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902463001/en/ La Tavolata by Barilla on the starting grid of the Monza circuit. More than two hundred people gathered around a single table: drivers, Team Principals, mechanics, engineers, strategists, safety and medical car drivers, personal trainers, tire technicians. The individuals whose collaboration, precision and trust shape every race, every decision and every performance. A nearly 100-meter table set with plates and pasta. With the first-ever Tavolata organized by Barilla and F1, people from across the Formula 1® ecosy
Aqara Showcases The New Smart Lighting Series and Immersive Smart Home Experience at IFA 20264.9.2026 11:30:00 CEST | Press release
Aqara, a global leader in IoT, today announced a new lineup of smart lighting products and a global community platform for smart space creators, at IFA 2026 in Berlin. The announcements reflect Aqara's ongoing vision for AI-driven spatial intelligence — spaces that understand their users and adapt to how people actually live in them. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260904365343/en/ Aqara Showcases The New Smart Lighting Series and Immersive Smart Home Experience at IFA 2026 The new lighting series — spanning indoor and outdoor use — integrates seamlessly with Aqara's existing ecosystem of sensors, switches, and hubs, bringing complete whole-space lighting scenarios and automated controls to life. The new Aqara products showcased include the Floor Lamp T1, LED Downlight T2, LED Strip T2, Outdoor String Lights H1, and Permanent Outdoor Lights H1. In addition, the company will present Aqara Builder, a platform fo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom